Ocular Therapeutix, Inc. (OCUL) vs uniQure N.V. (QURE)
- Ocular Therapeutix, Inc. OCUL 6.87 −6.91%
- uniQure N.V. QURE 21.72 −3.55%
Ocular Therapeutix, Inc. and uniQure N.V. are both Biotechnology companies. Ocular Therapeutix, Inc. and uniQure N.V. are of similar size ($1.6B and $1.6B). uniQure N.V. grew revenue faster over the last twelve months: 30.2% against −8.14%. Ocular Therapeutix, Inc. has the higher net margin (−579.1% vs −1,350.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Ocular Therapeutix, Inc. leads on 11 and uniQure N.V. on 6.
Valuation
Profitability
| Metric | OCUL | QURE | Biotechnology median |
|---|---|---|---|
| Gross margin | 87.11% | 92.49% | 65.16% |
| Operating margin | (603.04%) | (1,071.53%) | 0.00% |
| Net margin | (579.10%) | (1,350.73%) | 0.00% |
| Free cash flow margin | (490.07%) | (864.67%) | 0.00% |
| Return on equity | (72.99%) | (157.61%) | (56.36%) |
| Return on assets | (53.70%) | (32.13%) | (48.04%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack